**FOI Request re. Number of Patients Treated**

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

|  |  |  |
| --- | --- | --- |
| Drug | Number of patients treated between 01 February 2017 and 31 July 2018 | Number of patients treated between 01 August 2018 and 31 January 2020 |
| Apremilast | **0** | **0** |
| Adalimumab | **0** | **0** |
| Dupilumab | **0** | **0** |
| Etanercept | **0** | **0** |
| Infliximab | **6** | **\*Please see statement** |
| Secukinumab | **0** | **0** |
| Ustekinumab | **0** | **0** |

1. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

|  |  |
| --- | --- |
| Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 | Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020 |
| **0** | **0** |

1. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

|  |  |  |
| --- | --- | --- |
| Drug | Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 | Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020 |
| Apremilast | **0** | **0** |
| Adalimumab | **0** | **0** |
| Dupilumab | **0** | **0** |
| Etanercept | **0** | **0** |
| Infliximab | **0** | **0** |
| Secukinumab | **0** | **0** |
| Ustekinumab | **0** | **0** |

1. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

|  |  |
| --- | --- |
| Drug | OPCS code (e.g. X385 subcutaneous immunotherapy) |
| Apremilast | **X92.1** |
| Adalimumab | **X92.1** |
| Dupilumab | **X89.9** |
| Etanercept | **X92.1** |
| Infliximab | **X92.1** |
| Secukinumab | **X92.1** |
| Ustekinumab | **X89.1** |

1. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

|  |  |
| --- | --- |
| Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018 | Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020 |
| **N/A** | **N/A** |

The Walton Centre NHS Foundation Trust is a Specialist Neuroscience Tertiary Care Centre; we do not treat patients in homecare settings, therefore we cannot provide this information.

1. How many of your Trust’s homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

|  |  |  |
| --- | --- | --- |
| Drug | Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018 | Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020 |
| Apremilast | **N/A** | **N/A** |
| Adalimumab | **N/A** | **N/A** |
| Dupilumab | **N/A** | **N/A** |
| Etanercept | **N/A** | **N/A** |
| Infliximab | **N/A** | **N/A** |
| Secukinumab | **N/A** | **N/A** |
| Ustekinumab | **N/A** | **N/A** |

\* I confirm that The Walton Centre NHS Foundation Trust holds the information you have requested. However, I am unable to provide you with that information as I consider that the following exemptions apply to it:

**Section 40 (2) – Third Party Data**

This information is exempt from disclosure under Section 40(2) of the Freedom of Information Act 2000 (FOIA), due to the minimal number of patients identified, and in answering your query may lead to the undue stress of families and patients as this information may still lead to patients being identified. Therefore this information has not been released for reasons of confidentiality.

This exemption is not subject to the public interest test.

This response therefore acts as a refusal notice under section 17 of the FOIA.